2019
Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2018
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.Peer-Reviewed Original ResearchConceptsRisk of thrombosisPV patientsOverall survivalThrombotic eventsMultivariable Cox proportional hazards modelsEnd Results-Medicare databaseHigh-risk PV patientsCox proportional hazards modelOlder adultsImpact of phlebotomyRetrospective cohort studyPopulation-based studyProportional hazards modelEffect of phlebotomyOutcomes of interestPolycythemia vera patientsContemporary clinical practiceImproved OSCohort studyCytoreductive therapyOlder patientsTherapeutic phlebotomyTreatment modalitiesCurrent guidelinesLower risk
2013
Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders
Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL. Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders. Clinical Lymphoma Myeloma & Leukemia 2013, 13: 716-720. PMID: 24035715, PMCID: PMC3846604, DOI: 10.1016/j.clml.2013.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleGraft RejectionHumansImmunosuppression TherapyImmunotherapyLymphoproliferative DisordersMaleMiddle AgedOrgan TransplantationPrednisoneRituximabTreatment OutcomeVincristineWithholding TreatmentYoung AdultConceptsReduction of immunosuppressionMonomorphic PTLDMedian progression-free survivalMonomorphic posttransplant lymphoproliferative disorderGraft rejection ratePosttransplant lymphoproliferative disorderTreatment-related mortalityProgression-free survivalMulti-institutional settingGraft lossMedian OSComplete responseLymphoproliferative disordersCurrent guidelinesDisease progressionAggressive typePatientsChemoimmunotherapyPTLDComplete withdrawalImmunosuppressionCombination programStepwise approachWithdrawalExcellent results